Cd133+ Cell Infusion in Patients With Colorectal Liver Metastases.
Status:
Completed
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
Treatment of patients with metastatic colorectal carcinoma is surgical resection. Only 10-15%
of the patients will be candidates for curative resection. After response to chemotherapy
this figure rises 10-13% more. To perform the surgery it is necessary to have a sufficient
remnant liver volume (RLV), which allows maintaining optimal liver function after resection.
If the estimated RLV is insufficient preoperatively, portal venous embolization site (PVE) is
performed for compensatory hypertrophy, thus increasing the number of resections 19%. Still,
in 20% of these patients surgery can not be performed because RLV is not achieved or because
the disease progresses while waiting for growth. Therefore, it is necessary to improve liver
regeneration without promoting tumor growth. Studies on liver regeneration, have determined
that cells (CD133 +) are involved in the liver hypertrophy that occurs after hepatectomy.
CD133 + have been used to induce liver hypertrophy with encouraging results. This population
of CD133 +, can be selected from peripheral blood after stimulation with Granulocyte
colony-stimulating factor (G-CSF), being able to obtain a large number of them. The
investigators propose to treat patients who do not meet criteria for surgery because of
insufficient volume <40%, with CD133 + and portal embolization in order to carry out a
surgical resection in a second place.